Bioscience Managers Translation Fund I
Acrux is a pharmaceutical company dedicated to developing and commercialising generic and specialty topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised, through licensees, a number of pharmaceutical products in the US, Europe and other markets.
Acrux is developing a range of topical and dermatological generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.
Currently, Acrux has three pharmaceutical products approved and marketed and a portfolio of generic topical products in development. The launch of the generic versions of Axiron® made it no longer commercially viable to market Axiron® in the US, and the product was withdrawn from the US market on 5th September 2017.